Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Ornithine transcarbamylase deficiency

Orpha number ORPHA664
Synonym(s) OCT deficiency
OTC deficiency
Ornithine carbamoyltransferase deficiency
Prevalence 1-9 / 100 000
Inheritance X-linked recessive
Age of onset Childhood
ICD-10
  • E72.2
ICD-O -
OMIM
UMLS
  • C0268542
MeSH
  • D020163
MedDRA
  • 10052450

Summary

Ornithine carbamyl transferase deficiency is a frequent enzymatic disorder transmitted either as a recessive or dominant X-linked trait. Mutations with no residual enzyme activity are always expressed in hemizygote males by a very severe neonatal hyperammonemic coma that generally proves to be fatal. Heterozygous females are either asymptomatic or express orotic aciduria spontaneously or after protein intake. This identifies carriers. Females may also be affected by symptoms with various degrees of intensity, ranging from dislike for proteins to chronic vomiting, growth retardation, hypotonia, psychomotor retardation, hyperammonemic coma, or psychiatric disorders. In females, outcome is extremely variable, depending on the degree of inactivation of the muted X chromosome. Mutations leading to residual enzyme activity result in juvenile or even adult hyperammonemic coma in males, simulating Reye's syndrome or encephalitis. Females remain always asymptomatic. Diagnosis is based on the presence of hyperammonemia and chromatography of aminoacids evidencing major hypocitrullinemia and increased levels of glutamine, alanine, and lysine. High levels of urinary orotic acid are also a common finding during acute phases. Familial history with evidence of an X-linked disease is also strongly suggestive of the disorder. The diagnosis is confirmed by measuring enzymatic activity in liver or intestinal biopsies. Familial investigation is based on molecular analysis, which must be carried out in both affected and healthy relatives. Molecular gene analysis is also used for antenatal diagnosis. Patients are treated with a diet of limited protein intake adapted to their level of tolerance, arginine and citrulline supplementation, and both sodium benzoate and sodium phenylbutyrate. Some severe forms have been successfully treated by liver transplant.

Expert reviewer(s)

  • Pr Jean-Marie SAUDUBRAY

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image

Detailed information

Summary information
Emergency guidelines
  • EN (2012,pdf)
Clinical practice guidelines
  • EN (2012)
Article for general public
  • NL (2011,pdf)
  • ES (2011,pdf)
  • FR (2011,pdf)
  • IT (2011,pdf)
  • PT (2011,pdf)
  • DE (2011,pdf)
  • EN (2011,pdf)
Clinical genetics review
  • EN (2013)
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.